Not logged in Share Save
Share Save
Share Save
Share Save
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors Plummer, Ruth; Sodergren, Mikael H.; Hodgson, Rose; Ryan, Brid M.; Raulf, Nina; Nicholls, Joanna P.; Reebye, Vikash; Voutila, Jon; Sinigaglia, Laura; Meyer, Tim; Pinato, David J.; Sarker, Debashis; Basu, Bristi; Blagden, Sarah; Cook, Natalie; Evans, Thomas R. Jeffrey; Yachnin, Jeffrey; Chee, Cheng E.; Li, Daneng; El-Khoueiry, Anthony; Diab, Maria; Huang, Kai-Wen; Pai, Madhava; Spalding, Duncan; Talbot, Thomas; Noel, Marcus S.; Keenan, Bridget; Mahalingam, Devalingam; Song, Min-Sun; Grosso, Melanie; Arnaud, Denis; Auguste, Aurelie; Zacharoulis, Dimitris; Storkholm, Jan; Mcneish, Iain; Habib, Robert; Rossi, John J.; Habib, Nagy A. Share Save
LARP1 haploinsufficiency is associated with an autosomal dominant neurodevelopmental disorder Chettle, James; Louie, Raymond J.; Larner, Olivia; Best, Robert; Chen, Kevin; Morris, Josephine; Dedeic, Zinaida; Childers, Anna; Rogers, R. Curtis; Dupont, Barbara R.; Skinner, Cindy; Kury, Sebastien; Uguen, Kevin; Planes, Marc; Monteil, Danielle; Li, Megan; Eliyahu, Aviva; Greenbaum, Lior; Mor, Nofar; Besnard, Thomas; Isidor, Bertrand; Cogne, Benjamin; Blesson, Alyssa; Comi, Anne; Wentzensen, Ingrid M.; Vuocolo, Blake; Lalani, Seema R.; Sierra, Roberta; Berry, Lori; Carter, Kent; Sanders, Stephan J.; Blagden, Sarah P. Share Save
Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients Blagden, S.; Elshani, M.; Symeonides, S. N.; Skolariki, A.; Haris, N. R.; Boh, Z. Y.; Dickson, A.; Um, I. H.; Zhang, Y.; McKissock, F. G.; Oelmann, E.; Bloss, J.; Cook, N.; Evans, T. R. J.; Plummer, R.; Harrison, D. J. Share Save
Share Save
Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors Cook, Natalie; Blagden, Sarah; Lopez, Juanita; Sarker, Debashis; Greystoke, Alastair; Haris, Noor Md; Kazmi, Farasat; Anam, Kaiser; Franco, Ana Ortego; Pihlak, Rille; Goodwin, Louise; Wilson, David; Phillips, Caroline; Robertson, Jane; Timmis, Helen; Tilston, Craig; Woodcock, Simon A.; Plummer, Ruth Share Save
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301) Spiliopoulou, Pavlina; Kazmi, Farasat; Aroldi, Francesca; Holmes, Thomas; Thompson, David; Griffiths, Lucinda; Qi, Cathy; Parkes, Matthew; Lord, Simon; Veal, Gareth J.; Harrison, David J.; Coyle, Vicky M.; Graham, Jill; Jeffry Evans, Thomas R.; Blagden, Sarah P. Share Save
RNA regulatory disruption by 3′-dATP: A novel approach to inhibit ribosome biogenesis in cancer Elshani, Mustafa; Zhang, Ying; Um, In Hwa; Plummer, Ruth; Blagden, Sarah P.; Symeonides, Stefan N.; Cook, Natalie; Evans, T. R. Jeffry; Dickson, Alison L.; Harrison, David J. Share Save
Exposing the heterogeneity of the lipidome in the TME of cutaneous melanoma following treatment with NUC-7738 in combination with anti-PD-1 therapy Dickson, Alison L.; Zickuhr, Greice M.; Um, In Hwa; Zhang, Ying; Plummer, Ruth; Blagden, Sarah P.; Symeonides, Stefan N.; Cook, Natalie; Evans, T. R. Jeffry; Elshani, Mustafa; Harrison, David J. Share Save
NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302) Khan, Khurum; Mukherjee, Uma; Schlechter, Benjamin L.; Ciombor, Kristen K.; Skolariki, Aglaia; Coveler, Andrew L.; Graham, Janet S.; Peters, Mary Linton; Cohen, Stacey A.; Mettu, Niharika; Marijon, Helene; Cosgrove, David; McKissock, Fiona G.; Oelmann, Elisabeth; Bloss, Jeffrey D.; Blagden, Sarah P.; de Gramont, Aimery; Berlin, Jordan; Evans, T. R. Jeffry Share Save
NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 study Blagden, Sarah P.; Symeonides, Stefan N.; Skolariki, Aglaia; Hans, Noor Md; Boh, Zhuang; Um, In Hwa; Elshani, Mustafa; Dickson, Alison L.; Zhang, Ying; Harrison, David J.; McKissock, Fiona G.; Oelmann, Elisabeth; Bloss, Jeffrey D.; Cook, Natalie; Evans, T. R. Jeffry; Plummer, E. Ruth Share Save
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer Kristeleit, Rebecca; Plummer, Ruth; Jones, Robert; Carter, Louise; Blagden, Sarah; Sarker, Debashis; Arkenau, Tobias; Evans, Thomas R. Jeffry; Danson, Sarah; Symeonides, Stefan N.; Veal, Gareth J.; Klencke, Barbara J.; Kowalski, Mark M.; Banerji, Udai Share Save
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors Luke, Jason J.; Fakih, Marwan; Schneider, Charles; Chiorean, E. Gabriela; Bendell, Johanna; Kristeleit, Rebecca; Kurzrock, Razelle; Blagden, Sarah P.; Brana, Irene; Goff, Laura W.; O'Hayer, Kevin; Geschwindt, Ryan; Smith, Michael; Zhou, Feng; Naing, Aung Share Save
MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockade Plummer, Ruth; Sodergren, Mikael; Ryan, Brid; Tchakov, Ilian; Raulf, Nina; Hodgson, Rose; Tan, C. P.; Nicholls, Joanna P.; Adderkin, Alison; Vasileiadou, N.; Reebye, Vikash; Meyer, Tim; Pinato, David J.; Sarker, Debashis; Basu, Bristi; Blagden, Sarah; Cook, Natalie; Evans, Jeff; Yachnin, Jeffrey; Chee, Cheng Ean; Li, Dan; El-Khoueiry, Anthony; Diab, Maria; Huang, Kai-Wen; Noel, Marcus S.; Keenan, Bridget; Mahalingam, Devalingam; Grosso, Melanie; Arnaud, Denis; Auguste, Aurelie; Storkholm, Jan; McNeish, Iain; Habib, Robert; Rossi, John J.; Habib, Nagy Share Save
Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors Sarker, Debashis; Blagden, Sarah; Cook, Natalie; Evans, Thomas R.; Plummer, Ruth; Angelakas, Angelos; Bashir, Saira; El Badri, Salma; Mavroeidis, Leonidas; Morton, Cienne; Muhith, Abdul (Moe); White, Mark; Dixon, Rupert; Garric, Elodie; Mann, Joanne; Matthews, Ivan; Banerji, Udai Share Save
Share Save
INTERIM RESULTS FOR PHASE 1B DOSE EXPANSION OF MTL-CEBPA IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMOUR MALIGNANCIES Plummer, Ruth; Sodergren, Mikael; Ryan, Brid; Tachkov, Ilian; Reebye, Vikash; Meyer, Tim; Pinato, David; Sarker, Debashis; Basu, Bristi; Blagden, Sarah; Cook, Natalie; Evans, Jeff; Yachnin, Jeffrey; Chee, Cheng-Ean; Li, Daneng; El-Khoueiry, Anthony; Diab, Maria; Huang, Kai-Wen; D'Alessio, Antonio; Fulgenzi, Claudia; Noel, Marcus; Keenan, Bridget; Mahalingam, Devalingam; Raulf, Nina; Hogson, Rose; Tan, Choon Ping; Nicholls, Joanna; Adderkin, Alison; Vassiliadou, Julia; Habib, Robert; Rossi, John; Habib, Nagy Share Save
.png){kind=icon}
.png){kind=icon}
Not logged in.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
